Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
Publication Date
2015
Journal Title
J Bone Miner Res
Abstract
This work provides a systematic review of the literature from January 2003 to April 2014 pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and offers recommendations for its management based on multidisciplinary international consensus. ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab). The incidence of ONJ is greatest in the oncology patient population (1% to 15%), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of ONJ is estimated at 0.001% to 0.01%, marginally higher than the incidence in the general population (
Volume Number
30
Issue Number
1
Pages
3-23
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Dental Medicine
PMID
DOI
10.1002/jbmr.2405